{
  "guideline": {
    "id": "PA166272961",
    "name": "Annotation of FDA Label for abrocitinib and CYP2C19",
    "source": "FDA",
    "version": 5,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166272961",
    "relatedChemicals": [
      {
        "id": "PA166272921",
        "name": "abrocitinib",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166308321",
      "name": "Recommendation Annotation PA166308321",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166272921",
          "name": "abrocitinib",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452193820,
        "html": "<p>&quot;In patients who are known or suspected to be CYP2C19 poor metabolizers, the recommended dosage of CIBINQO [abrocitinib] is 50 mg once daily. If an adequate response is not achieved with CIBINQO 50 mg orally daily after 12 weeks, consider increasing dosage to 100 mg orally once daily. Discontinue therapy if inadequate response is seen after dosage increase to 100 mg once daily.&quot; See label for more information</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166308341",
      "name": "Recommendation Annotation PA166308341",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166272921",
          "name": "abrocitinib",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452193840,
        "html": "<p>&quot;In patients who are known or suspected to be CYP2C19 poor metabolizers, the recommended dosage of CIBINQO [abrocitinib] is 50 mg once daily. If an adequate response is not achieved with CIBINQO 50 mg orally daily after 12 weeks, consider increasing dosage to 100 mg orally once daily. Discontinue therapy if inadequate response is seen after dosage increase to 100 mg once daily.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Cibinqo (abrocitinib), NDA213871, Pfizer Laboratories Div Pfizer Inc",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213871"
    }
  ],
  "version": "2024-02-29-20-19"
}